Search

everythinglearnresearchcommunity

for

Search:↓

Possible link between androgens and COVID-19 severity; more research needed.

Certain natural compounds called terpenes may help prevent prostate cancer.

COVID-19 might affect male fertility, but more research is needed to understand the full impact.

Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.

The conclusion is that individual differences in COVID-19 severity are influenced by factors like age, sex, race, and genetics, which are important for personalized medicine.

The ACE1 gene variant doesn't affect long-COVID symptoms.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

Betacoronaviruses, like COVID-19, may cause hormone system dysfunction and affect disease susceptibility and severity.

Men and women get COVID-19 at similar rates, but men tend to get sicker and have a higher risk of dying, while women usually have stronger immune responses and vaccine reactions.

Sex hormones may affect COVID-19 severity, with men often faring worse, and targeting related pathways could offer treatment options.

Higher androgen levels might make COVID-19 worse, especially in men.

People with androgenetic alopecia may have a higher risk of severe COVID-19.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

Key genes can rewire networks, changing skin appendage types.

Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.

Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.

COVID-19 can cause different skin symptoms that may help with early diagnosis and show how severe the disease is.

Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.

Understanding where cancer cells come from helps create better prevention and treatment methods.

AGA linked to worse COVID-19 outcomes in men.

Long COVID patients may have hormonal imbalances linked to their symptoms.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

Mesenchymal stromal cells may help treat severe COVID-19, but more research is needed to confirm their effectiveness.

Low testosterone levels may lead to more severe COVID-19 outcomes.

Men with higher androgen levels may have severe COVID-19 symptoms, but those on antiandrogen therapy are less likely to contract the virus and have milder symptoms. Anti-androgen drugs could potentially treat COVID-19, but more research is needed.